Starna Therapeutics emerges with financing for mRNA vaccine and therapies

Starna Therapeutics has emerged with 150 million Yuan, or about $24 million, in Series A financing to take on two difficult areas in biotech R&D: RSV and idiopathic pulmonary fibrosis.